GTMRX
Price
$19.60
Change
-$0.06 (-0.31%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

GTMRX vs RPTIX

Header iconGTMRX vs RPTIX Comparison
Open Charts GTMRX vs RPTIXBanner chart's image
Goldman Sachs Small/Mid Cap Growth R
Price$19.60
Change-$0.06 (-0.31%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
GTMRX vs RPTIX Comparison Chart
Loading...
VS
GTMRX vs. RPTIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GTMRX is a StrongBuy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. GTMRX (1.84B). RPTIX pays higher dividends than GTMRX: RPTIX (0.18) vs GTMRX (0.00). GTMRX was incepted earlier than RPTIX: GTMRX (17 years) vs RPTIX (9 years). GTMRX is a more actively managed with annual turnover of: 62.00 vs. RPTIX (21.70). GTMRX has a lower initial minimum investment than RPTIX: GTMRX (0) vs RPTIX (500000). GTMRX annual gain was more profitable for investors over the last year : 27.50 vs. RPTIX (14.81). RPTIX return over 5 years is better than : 15.09 vs. GTMRX (0.20).
GTMRXRPTIXGTMRX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence17 years9 years-
Gain YTD13.3799.127147%
Front LoadN/AN/A-
Min. Initial Investment0500000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.84B31.4B6%
Annual Yield % from dividends0.000.18-
Returns for 1 year27.5014.81186%
Returns for 3 years-24.88-13.57183%
Returns for 5 years0.2015.091%
Returns for 10 years-2.19N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp